Lucid Diagnostics Secures Initial VA Orders, Showcases EsoGuard at DDW
summarizeSummary
Lucid Diagnostics has secured initial purchase orders from the Department of Veterans Affairs (VA) for its EsoGuard test, following its listing on the Federal Supply Schedule. The company also presented EsoGuard at Digestive Disease Week (DDW), highlighting its non-endoscopic tests in clinical guidelines. While the headline reiterates Q1 financial results, which were previously reported on May 13th showing a narrowing loss and 51.7% revenue growth, the VA orders represent a critical new revenue channel. With a contracted payment of $1,938 per test, this is a highly material development for a company that reported $1.26M in Q1 revenue and has a reiterated going concern warning. This provides a tangible path to future revenue growth and could alleviate some financial pressures. Traders will closely monitor the timing and magnitude of revenue generation from the VA contract and further adoption of EsoGuard.
At the time of this announcement, LUCD was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $207.1M. The 52-week trading range was $0.95 to $1.70. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.